Immune Checkpoints Equipment & Supplies In Malta
60 equipment items found
by:ALPHA-1 BIOLOGICS LLC based inSTONY BROOK, NEW YORK (USA)
Alpha-1 Biologics has developed orally-available small molecules including our lead molecule, Alpha-101. We have shown that Alpha-101 is safe and effective in mice for increasing immune cells. When combined with the PD-1 immune checkpoint inhibitor, Alpha-101 significantly decreases the growth of kidney tumors in mice. ...
Manufactured by:Synaffix BV based inOss, NETHERLANDS
Enabling immune cell engagers & other protein ...
Manufactured by:InnoPep Inc. based inSan Diego, CALIFORNIA (USA)
Programed cell death protein 1 (PD-1) is a cell surface receptor. PD-1 and its ligand PD-L1 are crucial immune checkpoints to downregulate T cell activation, tolerance and immunopathology. Several types of cancer cells overexpress PD-L1 in order to escape from the PD-1/PD-L1 immunosurveillance mechanism. Human PD-L1 inhibitor II is a peptide-based molecule. It binds to human PD-1 and inhibits ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
Bristol Myers Squibb is enrolling patients in the dose escalation phase of a Phase 1/2a clinical trial (NCT03994601) of a second anti-CTLA-4 Probody, BMS-986288, based on a modified version of Yervoy® (ipilimumab), to evaluate a CTLA-4-directed Probody therapeutic alone or in combination with Opdivo® (nivolumab) in patients with selected advanced solid cancers. CTLA-4, a clinically ...
Manufactured by:Elpiscience based inShanghai, CHINA
LAG3 is an immune checkpoint receptor known to suppress T cell activation. We designed ES005 to block LAG3 ligands, including MHC class II and FGL1. Through unique epitope binding, ES005 is able to recognize human LAG3 with high affinity. In preclinical studies, ES005 inhibited tumor growth both as a monotherapy and in combination with a PD-1 ...
Manufactured by:PharmAbcine Inc. based inYuseong-gu, SOUTH KOREA
PMC-309 is an engineered monoclonal antibody that targets the negative immune checkpoint human VISTA (V-domain Ig suppressor of T cell activation). It indirectly promotes T cells' immune responses by inhibiting VISTA-expressing immunosuppressive cells such as MDSCs (Myeloid-Derived Suppressor Cells) which suppress T cell inactivation and ...
by:Calviri based inPhoenix, ARIZONA (USA)
Calviri’s immunotherapy diagnostic is a huge leap forward in predicting therapy outcomes compared to current available ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso5 is a discovery-stage program leveraging a specific keystone gut bacteria (undisclosed) to potentiate the effects of Immune Checkpoint Blockade (ICB) drugs. The field of cancer therapy has been revolutionized by the use of immunotherapy. The microbiome breakthrough science today paves the way for innovative biotherapies to potentiate the effectiveness of these cancer immunotherapies. YSOPIA ...
Manufactured by:TC BioPharm based inHolytown, UNITED KINGDOM
TCB005 is an allogeneic CAR-T product which targets B7-H3 (also known as CD276). B7-H3 expression has been detected in a wide range of solid tumors including lung, breast, colorectal, liver and skin cancers. It has also been observed on tumor vasculature and stroma, has been hypothesized to be an immune checkpoint and to be expressed on cancer stem cells, making it promising target for the ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
BT-001 is the first oncolytic virus from Invir.IO™ and is optimized to act as a Trojan horse. Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was developed by BioInvent, and the cytokine GM-CSF, which triggers the body’s immune ...
Manufactured by:Elpiscience based inShanghai, CHINA
ES101 is a first-in-class tetravalent bispecific antibody targeting 4-1BB and PD-L1. It has a unique mechanism of action as 4-1BB activation is dependent on PD-L1 binding. 4-1BB is a T cell co-stimulatory receptor and is a compelling immune checkpoint target. 4-1BB targeting antibodies being developed by multinational companies have exhibited dose-dependent liver toxicity in clinical trials, ...
Manufactured by:Promega Corporation based inMadison, WISCONSIN (USA)
The antibodies used to stimulate T cell activation via interaction with co-stimulatory receptors on the effector cells can be cross-linked via binding to FcγRIIb receptors on CHO-K1 cells. Based on the properties of the antibody tested, the Co-Stimulatory Immune Checkpoint (i.e., OX40, CD40, GITR and 4-1BB) bioassays can be conducted in a single genetically engineered cell system or dual ...
by:Genmab A/S based inCopenhagen V, DENMARK
DuoBody-CD3xB7H4 (GEN1047) is a proprietary bispecific antibody created using Genmab’s DuoBody® technology. B7H4 is an immune checkpoint protein expressed on malignant cells in various solid cancers including breast, ovarian and lung cancer. In preclinical studies, DuoBody-CD3xB7H4 was shown to induce T-cell mediated cytotoxicity of B7H4-positive tumor ...
Manufactured by:Eutilex Co.,Ltd. based inSeoul, SOUTH KOREA
Fully humanized anti-human 4-1BB monoclonal antibody. Agonistic effect of EU101 promotes cytotoxic T lymphocyte response and it leads to eradication of ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
A novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets being developed by the Company to fight primary and secondary resistance mechanisms developed by cancers to evade checkpoint inhibitor ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
B7H3 belongs to the B7 family of immune checkpoint inhibitors and is expressed on a wide range of solid and hematologic malignancies. B7H3 is an important mediator of tumor angiogenesis and metastasis, and higher expression is associated with a poor prognosis for patients. We are developing FT573, an investigational, universal, off-the-shelf NK cell cancer immunotherapy derived from a clonal ...
by:Fusix Biotech based inMünchen, GERMANY
The FUSIX Technology relies on a fusion-based oncolytic virus platform. Below you can see FUB101 in action. In this timelapse video FUB101 is killing a monolayer of cancer cells (HCC) within 48 hours through a fusogenic mechanism of action. The FUSIX technology is based on a hybrid virus construct combining all the advantages of both parental platforms while minimizing risks factors. This ...
Manufactured by:MedGenome Inc. based inCounty of New Castle, DELAWARE (USA)
OncoPeptTUME — A novel in-silico approach to model the tumor microenvironment and predict treatment efficacy and long-term survival benefits for immunotherapy applications. Cancer immunotherapy is now established as a major therapeutic modality. Cancer immunotherapy drugs elicit their anti-tumor immune response in a subset of the treated patients by activating CD8 T-cells and provide ...
Manufactured by:Jubilant Therapeutics Inc. based inBedminster, NEW JERSEY (USA)
Strong scientific and clinical rationale for novel small molecule PD-L1 ...
Manufactured by:OncoQR ML GmbH based inBreitenfurt, AUSTRIA
Cancer cells have the ability to escape our immune system´s defenses – by outsmarting checkpoint molecules on our immune cells. For more than three decades, science and industry have been working to overcome cancer’s tricky battle ...